Skip to main navigation
Skip to main content
Skip to Footer
US
Novartis site directory
Our Products
US Products By Brand
Patient Assistance
Product Portfolio
Our Process
Therapeutic Areas
Product Related Issues
About Us
Novartis US at a Glance
Who We Are
Diversity & Inclusion
Our Leadership
Research
Contact Us
Corporate Responsibility
Novartis in Society US Reports
External Funding
Corporate Citizenship
Business Conduct
Corporate Integrity Agreement
Payments to HCPs & HCOs
Post-Marketing Commitments
Enhanced Verification Request
Beacon of Hope
News
News Archive
Statements
Stories
The STEP Program
US Media Contacts
Novartis US COVID-19 Initiatives
Careers
Careers Search
Working at Novartis
Career Paths
Career Programs
Employee Benefits
Awards & Recognition
NIBR Careers Frequently Asked Questions
Search
News Archive
Advanced Search
Basic Search
From Date:
To Date:
Show:
All
Media Releases
Stories
Filter By
2021
September
Media Release
/
Sep 17, 2021
Novartis announces findings from a real-world study of alpelisib demonstrating clinical benefit in people with PIK3CA-Related Overgrowth Spectrum (PROS)
Read More
August
Media Release
/
Aug 31, 2021
Novartis launches "Meet The PROS" to raise awareness and support education for PIK3CA-Related Overgrowth Spectrum (PROS)
Read More
Media Release
/
Aug 17, 2021
Novartis announces positive results from Phase III trials of BEOVU® in diabetic macular edema, including dosing intervals up to 16 weeks
Read More
July
Media Release
/
Jul 20, 2021
Novartis pledges 10-year commitment with Morehouse School of Medicine, 26 Historically Black Colleges, Universities, Medical Schools and other leading organizations to co-create effective, measurable solutions for health equity
Read More
June
Media Release
/
Jun 04, 2021
Novartis investigational checkpoint inhibitor tislelizumab met primary endpoint of overall survival in pivotal Phase III trial of esophageal cancer after systemic therapy
Read More
Media Release
/
Jun 04, 2021
Novartis announces Tabrecta® first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC
Read More
Media Release
/
Jun 03, 2021
Novartis 177Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer in Phase III VISION study
Read More
Media Release
/
Jun 02, 2021
Novartis Kymriah® pivotal trial demonstrates strong response rates and a remarkable safety profile in relapsed or refractory follicular lymphoma
Read More
Media Release
/
Jun 02, 2021
Novartis Kisqali® reports longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patients
Read More
Media Release
/
Jun 01, 2021
Novartis Cosentyx receives FDA approval for treatment of children and adolescents with moderate to severe plaque psoriasis
Read More
Search Results Navigation
First page
« first
Previous page
‹ previous
Page
1
of 5
Page
2
of 5
Current page
3
of 5
Page
4
of 5
Page
5
of 5
…
Next page
next ›
Last page
last »
Share
Twitter
Facebook
LinkedIn
Email
Whatsapp
Jump to Comments
Print
Save
Related Links
News
You are here
Home
›
News